Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment-Reference-Cited by-同舟云学术

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment

Published:2017-03-05 Issue:5 Volume:130 Page:559-565
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Li Ming-Hui,Zhang Lu,Qu Xiao-Jing,Lu Yao,Shen Ge,Wu Shu-Ling,Chang Min,Liu Ru-Yu,Hu Lei-Ping,Li Zhen-Zhen,Hua Wen-Hao,Song Shu-Jing,Xie Yao

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference32 articles.

1. A decade-old change in the screening rate for hepatocellular carcinoma among a hepatitis B virus-infected population in Korea;Kim;Chin Med J,2016

2. Interferon treatment for hepatitis B;Konerman;Clin Liver Dis,2016

3. Spontaneous relapse of hepatitis in inactive HBsAg carriers;Chu;Hepatol Int,2007

4. Long-term outcome of chronic hepatitis B in caucasian patients: Mortality after 25 years;Fattovich;Gut,2008

5. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a;Li;World J Hepatol,2016

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between Phenotypic Changes of Dendritic Cell Subsets and the Onset of Plateau Phase during Intermittent Interferon Therapy in Patients with CHB;BIOMED ENVIRON SCI;2024

2. Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy;BMC Infectious Diseases;2023-07-10

3. Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy;2023-03-14

4. Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy;Frontiers in Immunology;2023-01-30

5. Dynamic changes of the proportion of HLA-DR and CD38 coexpression subsets on T lymphocytes during IFN-based chronic hepatitis B treatment;Frontiers in Immunology;2023-01-24